Adagene Inc
NASDAQ:ADAG
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.44
4.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Adagene Inc
Adagene Inc
Total Equity
Adagene Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adagene Inc
NASDAQ:ADAG
|
Total Equity
$70.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Equity
¥25.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Equity
¥2.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Equity
¥12.7B
|
CAGR 3-Years
71%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Equity
¥30.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Equity
¥31.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
44%
|
CAGR 10-Years
29%
|
|
Adagene Inc
Glance View
Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
See Also
What is Adagene Inc's Total Equity?
Total Equity
70.6m
USD
Based on the financial report for Dec 31, 2023, Adagene Inc's Total Equity amounts to 70.6m USD.
What is Adagene Inc's Total Equity growth rate?
Total Equity CAGR 5Y
10%
Over the last year, the Total Equity growth was -15%. The average annual Total Equity growth rates for Adagene Inc have been 3% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
